REPL
Replimune Group, Inc.
Biotechnology · Healthcare · United States
17.61
close · 2026-10-30
value
60
cheaper than peers60
quality
10
stronger fundamentals10
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -17.0% | 67 |
| earnings yield, 2 years ago | -18.4% | 64 |
| cash flow yield, 3 years ago | -7.8% | 62 |
| earnings yield, 1 year ago | -17.4% | 61 |
| cash flow yield, 1 year ago | -11.9% | 58 |
| cash flow yield, 2 years ago | -11.4% | 57 |
| earnings yield, latest year | -19.2% | 56 |
| cash flow yield, latest year | -17.0% | 52 |
| price to book | 8.15× | 19 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -134.3% | 21 |
| debt to equity | 106.0% | 9 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$171.7M |
| employees | 465 |
| first trade | 2018-07-20 |
| next earnings | 2026-10-28 |
| fundamentals updated | 2026-10-28 |
Annual history
| measure | 2026 | 2025 | 2024 | 2023 |
| diluted eps | -3.38 | -3.07 | -3.24 | -2.99 |
| free cash flow | -$284.6M | -$198.9M | -$191.1M | -$130.3M |
| net income | -$313.9M | -$247.3M | -$215.8M | -$174.3M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $13.6M | $21.1M | $23.4M | $10.0M |